• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

What The Government's Latest Asian-American Health Report Got Wrong
Asian-Americans fare better than the general population on five different measures of health, according to a new national study.  But though it may appear that the "model minority" myth about the 15 million Asians in America extends even to physical and mental health, experts say this finding obscures the truth about vast disparities between Asian subgroups -- and that the study's methodology may have prevented the elderly, immigrants and people who don't speak English from contributing to a more nuanced picture of the health status of Asians in America.  The report, published by the U.S. Center fo...
Source: Science - The Huffington Post - May 20, 2016 Category: Science Source Type: news